Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Fineline Cube Dec 31, 2025
Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Fineline Cube Dec 31, 2025
Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Fineline Cube Dec 31, 2025
Company Deals

Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline

Fineline Cube Dec 31, 2025
Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Fineline Cube Dec 30, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Fineline Cube Dec 31, 2025
Company Drug

Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy

Fineline Cube Dec 31, 2025
Company Deals

Hantech Medical Device Co., Ltd Acquires BD’s Villamarzana Factory to Expand Manufacturing

Fineline Cube Dec 10, 2024

China-based Hantech Medical Device Co., Ltd, a Contract Development Manufacturing Organization (CDMO) specializing in medical...

Company Deals

Precision Biotech and T&L Biotechnology Form Partnership to Advance Cell and Gene Therapies

Fineline Cube Dec 10, 2024

China-based Precision Biotech has announced a strategic partnership with compatriot firm T&L Biotechnology Co., Ltd....

Company Medical Device

MicroPort Scientific Corp. Launches FireFalcon Balloon for Coronary Interventions with NMPA Approval

Fineline Cube Dec 10, 2024

Shanghai-based medical device giant MicroPort Scientific Corp., (HKG: 0853) has announced that it has received...

Company Drug

HuidaGene Therapeutics Initiates HERO Trial for RNA-Editing Therapy HG204 in MECP2 Duplication Syndrome

Fineline Cube Dec 10, 2024

Shanghai-based HuidaGene Therapeutics has announced the first subject dosing of the HERO clinical trial, which...

Company Drug

Simcere Pharmaceutical’s SIM0508 Reaches First Patient Dosing in Global Clinical Study

Fineline Cube Dec 10, 2024

China-based Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary, Simcere Zaiming, has announced the first patient...

Company Deals

Livzon Pharmaceutical Group Inks Influenza Vaccine Patent Deal with South China Vaccine Corporation

Fineline Cube Dec 10, 2024

China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has entered into a significant patent and technology...

Company Deals

WuXi AppTec’s Subsidiary Invests EUR 20 Million in Jeito II S.L.P. for Growth Expansion

Fineline Cube Dec 9, 2024

China-based Contract Development and Manufacturing Organization (CDMO) WuXi AppTec Co., Ltd (SHA: 603259) has announced...

Company Drug

TJ Biopharma and Jumpcan Pharmaceutical Announce NMPA Review of Eftansomatropin Alfa BLA

Fineline Cube Dec 9, 2024

Chinese partners TJ Biopharma and Jumpcan Pharmaceutical (SHA: 600566) have jointly announced that the National...

Company Drug

AstraZeneca’s Imfinzi Receives FDA Priority Review for Muscle-Invasive Bladder Cancer

Fineline Cube Dec 9, 2024

UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has announced that the US Food and Drug...

Company Drug

Amgen’s Blincyto Meets Primary Endpoint in Phase III AALL1731 Study for Pediatric B-ALL

Fineline Cube Dec 9, 2024

US-based biotechnology company Amgen (NASDAQ: AMGN) has published the results from the Phase III study...

Company Drug

Novartis’ Fabhalta Demonstrates Positive Results in APPULSE-PNH Phase IIIb Study

Fineline Cube Dec 9, 2024

Swiss pharmaceutical major Novartis (NYSE: NVS) has released positive topline results from the APPULSE-PNH Phase...

Company Deals

Jiaxing Pharbers Genesis Secures RMB 100 Million in Series A2 Financing for Radiopharmaceuticals Expansion

Fineline Cube Dec 9, 2024

China-based Jiaxing Pharbers Genesis has reportedly raised RMB 100 million (USD 13.74 million) in a...

Company Deals

Novo Holdings’ Acquisition of Catalent Gets EU Nod, Paving Way for Novo Nordisk Expansion

Fineline Cube Dec 9, 2024

The acquisition of contract development and manufacturing organization (CDMO) Catalent (NYSE: CTLT) by Novo Holdings...

Company Drug

Johnson & Johnson’s Darzalex Faspro Showcases Clinical Efficacy in Multiple Myeloma at ASH 2024

Fineline Cube Dec 9, 2024

US healthcare conglomerate Johnson & Johnson (J&J, NYSE: JNJ) has presented results from several clinical...

Company Drug

AstraZeneca’s Imfinzi Demonstrates Positive Outcomes in PACIFIC-5 III Study for NSCLC

Fineline Cube Dec 9, 2024

UK-based pharmaceutical company AstraZeneca (AZ, NASDAQ: AZN) has announced positive results from the PACIFIC-5 III...

Company Drug

Duality Biologics’ BNT324/DB-1311 Shows Positive Results in Global Phase I/IIa Study at ESMO Asia

Fineline Cube Dec 9, 2024

Duality Biologics, a developer of antibody conjugate drugs (ADCs) with operations in the United States...

Company Drug

Innovent Biologics’ IBI343 Shows Promising Results in Phase I Study for Pancreatic Cancer at ESMO Asia

Fineline Cube Dec 9, 2024

China-based biopharmaceutical company Innovent Biologics, Inc. (HKG: 1801) presented updated data from the Phase I...

Company Deals

Hainan Haiyao Secures Exclusive Rights for AFT Pharmaceuticals’ Nutritional Products in China

Fineline Cube Dec 9, 2024

China-based Hainan Haiyao Co., Ltd (SHE: 000566) has announced a significant licensing agreement with Australia-based...

Company Drug

Novartis’ Scemblix Demonstrates Superior MMR Rates in Phase III ASC4FIRST Study

Fineline Cube Dec 9, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) unveiled longer-term results from the pivotal Phase III ASC4FIRST...

Company Drug

Tecvayli (Teclistamab) Demonstrates Positive Results in MajesTEC-5 and MajesTEC-4 Trials

Fineline Cube Dec 9, 2024

Janssen-Cilag International NV, a subsidiary of US healthcare giant Johnson & Johnson (J&J; NYSE: JNJ),...

Posts pagination

1 … 187 188 189 … 603

Recent updates

  • Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal
  • HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review
  • NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion
  • Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China
  • Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.